Driving Therapeutic Innovation in Neurodegenerative Disease With Hydrogen Deuterium eXchange Mass Spectrometry
Molecular & Cellular Proteomics · 2025
DOI: 10.1016/j.mcpro.2025.101017 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecular & Cellular Proteomics, 2025. Verfasst von Andrea Pierangelini und 2 weiteren Autor:innen. Beteiligte Einrichtung: Target Discovery Institute, Centre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom. Hauptthemen laut MEDLINE: Neurodegenerative Diseases, Hydrogen Deuterium Exchange-Mass Spectrometry. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 242 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Alzheimer’s Research UK, University of Oxford.
Abstract (Originalsprache)
Human neurodegenerative conditions such as Parkinson's and Alzheimer's disease are characterized by the formation and deposition of toxic protein species which exacerbate neuronal dysfunction, impacting the structure and function of the healthy brain. Deciphering the mechanisms underlying protein (mis)folding and aggregation is not only essential for a more coherent view of neurodegeneration, but also crucial for the development of novel therapeutics targeting this family of disorders. Key pathological drivers of neurodegeneration, such as alpha-synuclein and tau proteins, have traditionally proved extremely challenging to characterize structurally due to their intrinsic and widespread structural plasticity. Hydrogen-Deuterium eXchange Mass Spectrometry has emerged as a powerful tool to help circumvent this, owing to its ability to capture protein intrinsic disorder in solution, in addition to the transient structural conformations that typify protein aggregation pathways. This review brings together the most recent research where Hydrogen-Deuterium eXchange Mass Spectrometry has shed light on mechanisms of neurodegeneration. We highlight how the technique has been successfully integrated into therapeutic development workflows targeting some of the most prevalent neurodegenerative diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Target Discovery Institute, Centre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
- Target Discovery Institute, Centre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom. Electronic address: darragh.obrien@ndm.ox.ac.uk.
Förderung
- Alzheimer’s Research UK
- University of Oxford
Zitieren
APA
Pierangelini, A., Kessler, B. M., & O'Brien, D. P. (2025). Driving Therapeutic Innovation in Neurodegenerative Disease With Hydrogen Deuterium eXchange Mass Spectrometry. Molecular & Cellular Proteomics. https://doi.org/10.1016/j.mcpro.2025.101017
Vancouver
Pierangelini A, Kessler BM, O'Brien DP. Driving Therapeutic Innovation in Neurodegenerative Disease With Hydrogen Deuterium eXchange Mass Spectrometry. Molecular & Cellular Proteomics. 2025. doi:10.1016/j.mcpro.2025.101017
BibTeX
@article{Pierangelini2025,
author = {Pierangelini, Andrea and Kessler, Benedikt M and O'Brien, Darragh P},
title = {Driving Therapeutic Innovation in Neurodegenerative Disease With Hydrogen Deuterium eXchange Mass Spectrometry},
journal = {Molecular & Cellular Proteomics},
year = {2025},
doi = {10.1016/j.mcpro.2025.101017}
}
EUVIMED